STOCK TITAN

Praxis Precision Medicines, Inc. - PRAX STOCK NEWS

Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. By leveraging genetic insights, Praxis aims to address conditions ranging from major depressive disorder to epilepsy.

The company's lead product candidates include:

  • Prax-114: An extrasynaptic-preferring GABAA receptor positive allosteric modulator, currently in Phase IIa trials for treating major depressive disorder and perimenopausal depression.
  • Prax-944: A selective small molecule inhibitor of T-type calcium channels, in Phase IIa trials for essential tremor treatment.
  • Prax-562: A persistent sodium current blocker in Phase I trials aimed at severe pediatric epilepsy and adult cephalgia.
  • Prax-222 (Elsunersen): An antisense oligonucleotide targeting gain-of-function SCN2A epilepsy, under collaboration with Ionis Pharmaceuticals and RogCon, Inc.
  • PRAX-628: A next-gen small molecule targeting sodium-channels in the brain, being developed as a treatment for focal epilepsy.
  • Ulixacaltamide: A small molecule inhibitor for essential tremor, currently in late-stage development.

Recent news highlights include a partnership with Tenacia to extend ulixacaltamide's reach to Greater China, and advances in the PRAX-628 program demonstrating its potential as a best-in-class epilepsy drug.

Financially, Praxis has shown significant progress. As of the latest reports, the company has sufficient funding to continue operations into 2027, driven by strategic public offerings and a lean operational model.

For more details, visit www.praxismedicines.com and follow them on social media channels.

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced that its Compensation Committee has granted non-qualified stock options and restricted stock units to a new non-executive employee under its 2024 Inducement Plan. This plan is used to attract new talent under Nasdaq Listing Rule 5635(c)(4). The grants include stock options to purchase 300 shares and restricted stock units covering 225 shares of common stock. The exercise price of the options is $47.05 per share, matching the closing price on the Nasdaq Global Select Market as of June 3, 2024. The stock options will vest over four years, with 25% vesting after the first year and the remaining vesting equally over the subsequent three years. Similarly, the restricted stock units will vest in four equal annual installments, contingent on the employee’s continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced its participation in three upcoming investor conferences. Praxis will attend the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on May 20, 2024, with a live webcast available. The company will also be at the Mizuho Securities USA Neuroscience Summit in Boston on May 21, 2024. Additionally, Praxis will join the Jefferies Global Healthcare Conference in New York on June 6, 2024, with a live webcast available. Replay of the webcasts will be accessible on the company's website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
Rhea-AI Summary

Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for Q1 2024. The company plans to initiate two efficacy studies for PRAX-628, continues recruitment for Essential3 trials, and completed a public offering, resulting in cash of $451.2 million. Key developments include positive results for PRAX-628, expected topline results for Essential3 in H2 2024, and PRAX-562 Phase 2 EMBOLD study results in Q3 2024. Praxis aims to submit a NDA for ulixacaltamide in 2025 and is progressing with Elsunersen for SCN2A GoF DEEs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
Rhea-AI Summary

Praxis Precision Medicines, Inc. will release its first quarter 2024 financial results on May 13, 2024. The company focuses on developing therapies for CNS disorders related to neuronal excitation-inhibition imbalance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
conferences earnings
-
Rhea-AI Summary

Praxis Precision Medicines, Inc. announced the granting of non-qualified stock options and restricted stock units to six new non-executive employees under the 2024 Inducement Plan. The options have an exercise price of $55.16 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments. This move aims to attract and retain top talent for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announces the presentation of two abstracts at the American Academy of Neurology 2024 Annual Meeting showcasing progress in evaluating ulixacaltamide for essential tremor. The innovative Phase 3 clinical program sets a new standard for future trials in CNS disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in upcoming healthcare conferences in April, including the Needham 23rd Annual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium. The company aims to showcase its genetic insights-driven therapies for CNS disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. granted non-qualified stock options and restricted stock units to a new non-executive employee under the 2024 Inducement Plan. The options have an exercise price of $58.60 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering, raising approximately $200 million. The offering includes 3,318,585 shares of common stock and pre-funded warrants. Praxis granted underwriters an option for additional shares, with the closing expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of common stock and prefunded warrants to certain investors. The offering, managed by Piper Sandler, Guggenheim Securities, and Truist Securities, includes an option for underwriters to purchase additional shares. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags

FAQ

What does Praxis Precision Medicines, Inc. specialize in?

Praxis specializes in developing therapies for CNS disorders characterized by neuronal imbalance, leveraging genetic insights for innovative treatments.

What are the primary product candidates of Praxis?

Praxis' key product candidates include Prax-114, Prax-944, Prax-562, Prax-222 (Elsunersen), PRAX-628, and Ulixacaltamide.

What is the status of Prax-114?

Prax-114 is in Phase IIa clinical trials for the treatment of major depressive disorder and perimenopausal depression.

How is Praxis advancing its epilepsy treatments?

Praxis is developing PRAX-562 and PRAX-628, with the latter showing strong potential as a best-in-class focal epilepsy treatment.

What are recent corporate milestones for Praxis?

Recent milestones include strategic partnerships, ongoing clinical trials, and financial progress ensuring operations funding into 2027.

Can you provide financial details on Praxis' operations?

As of the latest reports, Praxis has $243.3 million in cash, cash equivalents, and marketable securities, with funding expected to last into 2027.

How can I stay updated on Praxis' developments?

Visit https://www.praxismedicines.com and follow them on Facebook, LinkedIn, and Twitter/X for the latest updates.

What partnerships has Praxis recently announced?

Praxis recently partnered with Tenacia to extend ulixacaltamide's reach to Greater China and continues collaborations with Ionis Pharmaceuticals and RogCon, Inc.

What is Ulixacaltamide, and what is its current development stage?

Ulixacaltamide is a selective small molecule inhibitor for essential tremor, currently in late-stage development.

Where can I find more information about Praxis' clinical studies?

You can learn more about Praxis' clinical studies on their official website, www.praxismedicines.com, and specific study sites like www.praxisessentialtremor.com.

Praxis Precision Medicines, Inc.

Nasdaq:PRAX

PRAX Rankings

PRAX Stock Data

940.25M
17.11M
0.18%
93.17%
5.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON